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Abstract
Background: The incidence of venous ulceration is rising with the increasing age of the general population.
Venous ulceration represents the most prevalent form of difficult to heal wounds and these problematic wounds
require a significant amount of health care resources for treatment. Based on current knowledge multi-layer high
compression system is described as the gold standard for treating venous ulcers. However, to date, despite our
advances in venous ulcer therapy, no convincing low cost compression therapy studies have been conducted and
there are no clear differences in the effectiveness of different types of high compression.
Methods/Design: The trial is designed as a pilot multicentre open label parallel group randomised trial. Male and
female participants aged greater than 18 years with a venous ulcer confirmed by clinical assessment will be
randomised to either the intervention compression bandage which consists of graduated lengths of 3 layers of
elastic tubular compression bandage or to the short stretch inelastic compression bandage (control). The primary
objective is to assess the percentage wound reduction from baseline compared to week 12 following
randomisation. Randomisation will be allocated via a web based central independent randomisation service
(nQuery v7) and stratified by study centre and wound size ≤ 10 cm
2 or >10 cm
2. Neither participants nor study
staff will be blinded to treatment. Outcome assessments will be undertaken by an assessor who is blinded to the
randomisation process.
Discussion: The aim of this study is to evaluate the efficacy and safety of two compression bandages; graduated
three layer straight tubular bandaging (3L) when compared to standard short stretch (SS) compression bandaging
in healing venous ulcers in patients with chronic venous ulceration. The trial investigates the differences in clinical
outcomes of two currently accepted ways of treating people with venous ulcers. This study will help answer the
question whether the 3L compression system or the SS compression system is associated with better outcomes.
Trial Registration: ACTRN12608000599370
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Venous disease is the most common cause of leg ulcers
[1,2]. The refractory nature of venous ulcers affects the
quality of life and work productivity of those persons
afflicted [3]. This, in combination with the high costs of
long-term therapy, makes venous ulcers a major health
problem in developed countries. Management of venous
leg ulcers is based on understanding pathophysiologic
abnormalities [4,5]. Compression increases ulcer healing
rates compared with no compression. Multi-layered sys-
tems are more effective than single-layered systems[6]
High compression is more effective than low compres-
sion but there are no clear differences in the effective-
ness of different types of high compression[6].
The short stretch compression system is often used as
a standard treatment in mainland Europe and Australia.
It is an inelastic bandage that has minimal extensibility
when applied[7]. The main disadvantage of short stretch
bandages is that they tend to become loose after a few
hours of wear time and tend to slip down the leg[8].
Short stretch bandage application also requires the skill
of experienced health care professionals[7] whereas elas-
tic tubular bandages can be applied by patients and
carers[8].
Application of the 3L elastic tubular system is very
simple; it can be applied in minutes and does not
require a trained health professional. The short stretch
bandage needs to be applied by a trained practitioner
and takes longer to apply. In some instances if applied
incorrectly can cause damage to underlying tissues on
the lower limb. In view of recent literature [9] that has
demonstrated that community nurses were unwilling to
use compression bandages because they were uncertain
of which type of compression bandage to use, and also
how to apply bandages. The 3L elastic compression sys-
tem may be more acceptable to nurses who apply com-
pression. The 3L elastic system may also increase the
number of patients in the community who are willing
to wear compression. There is evidence that some
patients with venous ulcers have increasing difficulty in
complying to compression bandaging[10]. The reasons
for and determinants of non-adherent behaviour to
compression is multifactorial and include pain, discom-
fort and lack of valid lifestyle advice by healthcare pro-
fessionals [11].
The aim of this study is to compare the efficacy and
safety of two high compression bandages in healing
venous ulcers in patients with chronic venous ulcera-
tion; graduated three layer straight tubular bandaging
(3L) compared to standard short stretch (SS) compres-
sion bandaging. The 3L compression bandage is easy to
apply, needs little, if any, training to apply to the limb,
is well tolerated by patients and is cost effective.
Venous leg ulcer Incidence
Chronic leg ulcers are leg ulcers which have not healed
themselves in a four week period. Chronic leg ulcers
affect 1% of the general population in Australia [4], and
3.6% of people older than 65 years [5].
Venous ulceration represents the most prevalent form
of difficult to heal wounds and these problematic
wounds require a significant amount of health care
resources for their treatment. The incidence of venous
ulceration is rising with the increasing age of the general
population. The most common cause of lower extremity
ulcers is venous insufficiency and accounts for nearly
80% of all ulcers [12,13].
Risk factors for development of venous ulcers include
venous disease, obesity, immobility, phlebitis, family his-
tory of varicose veins, deep vein thrombosis, previous
surgery for varicose veins and congestive cardiac failure.
Up to 50% of patients with chronic venous insufficiency
have a history of leg injury [12,13].
Aetiology of venous ulcers
The pathophysiology of venous ulceration is controver-
sial [13] however it is believed that ulcers result from
venous occlusion or valvular incompetence and subse-
quent superficial venous hypertension [14]. Venous leg
ulcers occur as a result of underlying venous disease
where damage has occurred to the superficial deep or
perforating veins. Although aetiology of venous ulcera-
tion is unclear, it has been suggested that ulceration
results from increased intraluminal pressure in the capil-
laries. This results in fibrin deposition around the capil-
laries [15]. White blood cells are activated and release
proteolytic enzymes that cause further tissue destruc-
tion. The alternative ‘Trap’ hypothesis proposes that
fibrin and macromolecules eventually leak into the der-
mis where they bind with growth factors, making then
unavailable for the tissue repair process.
The most recent theories about pathogenesis of
venous ulcer have associated it with microcirculatory
abnormalities and generation of an inflammatory
response. The molecular and cellular profiles of chronic
skin wound wounds are substantially different than
found in acute healing wounds. Healing time is influ-
enced by patient age, ulcer duration and ulcer area, but
not by type of venous incompetence [15,16]
Diagnosis of venous ulcers
In most instances, diagnosis of venous ulceration may
be made using clinical criteria alone; however in 25% of
cases leg ulcers will have mixed characteristics. The
ankle-brachial index is a common vascular assessment
to determine underlying aetiology although the gold
standard in evaluating venous disease is considered to
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the ankle-brachial index is measured using a Doppler to
exclude arterial disease.
Treatment of venous ulcers
The mainstay treatment of leg ulcers is sustained gradu-
ated high compression bandaging of the affected limb
[18]. This acts by reducing the abnormally high pressure
seen in the superficial veins and underlying lower limb
swelling and oedema. Healing can be expedited through
elevation of the affected limb, improved mobility, weight
reduction, and improved nutrition. High compression
bandaging systems may be delivered using either elastic
or inelastic bandaging. A recent meta-analysis of banda-
ging systems found that multilayer compression ban-
dages seemed to be superior to single-layer bandages in
promoting ulcer healing [18]. Based on current knowl-
edge the multi-layer high compression system is
described as the current gold standard for treating
venous ulcers. However, to date, despite our advances in
venous ulcer therapy, no convincing low cost compres-
sion therapy studies have been conducted. And although
we know that high compression is more effective than
low compression there are no clear differences in the
effectiveness of different types of high compression.
Venous ulcer healing
Venous leg ulcer healing rates vary considerably. In
wound centres providing graduated compression banda-
ging treatment for venous ulcers, healing rates vary
from 25 to 50% after 12 weeks to 40% - 70% at 12
weeks [19] and after two years of compression therapy
20% of all chronic venous leg ulcers remain unhealed
and even when healing does occur, approximately 56%
will recur [3].
There are many reasons for variation in treatment
times for venous ulcers. Chronic wounds that measure
less than 10 cm
2 and are present for less than 12
months at first treatment are likely to be healed in 71%
of patients within 24 weeks of treatment [20]. Conver-
sely, chronic wounds that were greater than 10 cm
2 and
have been present for more than 12 months, had only a
22% likelihood of being healed within the 24 week per-
iod. High compression is more effective than low com-
pression but there are no clear differences in the
effectiveness of different types of high compression [18].
Economic and personal burden of venous ulcers
The impact of leg ulcers is felt both in physical suffering
and reduced quality of life of those affected and in
financial costs to the community [21]. Analysis per-
formed more than ten years ago in Australia estimated
that venous ulcers were responsible for about $400 mil-
lion annually in health care costs. The high prevalence
of venous ulcer has a significant socioeconomic impact
in terms of medical care, days off work and reduced
quality of life [4]. Treatment of venous ulcers is both
time consuming and costly. Most of this cost is asso-
ciated with the supply of dressings including multi layer
bandages and community nurse visits [17].
The projected cost of management of venous ulcers is
significant. Currently, up to 20 per 1000 individuals over
the age of 80 have an active leg ulcer. One in eight Aus-
tralians are aged over 65 years. By 2044 those aged over
65 years will account for one in four Australians. The
expected number of people aged over 65 years living in
western societies is anticipated to double within the next
40 years or so. Because the cost and resource implication
of management of venous ulcers will cause considerable
strain on the health system, strategies to improve man-
agement and cost effectiveness of this condition must be
seen as a priority. Leg ulceration is a chronic condition,
t h ep r e v a l e n c eo fw h i c hi sl i k e l yt oi n c r e a s ea sp o p u l a -
tions age [22]. Leg ulcers are reported as having an
impact on virtually every aspect of daily life: pain is com-
mon, sleep is often impaired, mobility and work capacity
tend to be restricted, personal finances are often
adversely affected [23], and social activities are restricted
due to fear of injury and negative body image [24].
Chronic venous ulcer healing remains a complex clini-
cal situation and often requires the intervention of
skilled, but costly multidisciplinary wound care teams.
Venous leg ulcers that have been present for a pro-
longed period of time pose a substantial management
challenge for clinicians. Traditional treatment options
have often been ineffective or associated with several
drawbacks. Although multi layer compression therapy is
the standard care provided for management of venous
leg ulcers, we are still unsure of the optimum level of
compression needed to heal venous ulcers. There is a
need to assess the healing efficacy of the two compres-
sion bandaging systems in the management of people
with venous ulceration. The three layer compression
system is cheaper alternative and may improve potential
for patients to tolerate and comply with wearing com-
pression bandages.
Methods/Design
Rationale for Conducting the Trial
This pilot study is being conducted to assess the healing
efficacy and safety of a graduated three layer straight
tubular bandaging system when compared to standard
compression bandaging system in the management of
people with venous ulceration. Indications of increased
venous ulcer healing efficacy of the 3 layer compression
system may provide a basis for greater compliance from
patients and therefore improve healing rates. As an easy
to apply, economical compression system this
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venous ulcers. We plan to recruit sufficient numbers at
each site to test recruitment strategy and recruitment
rate to inform a national study.
Summarized Details of Investigational Products
The Investigational Product being studied is Tubular -
Form; an elastic tubular bandage. Tubular form is listed
with TGA (AUST L 59144) as a treatment for varicose
conditions and control of oedema. In this study the
investigational product will be used in graduated lengths
of 3 layers of the tubular bandage system as follows:
1. from base of toes to just under knee (long layer)
2. from base of toes to above calf pump (medium
layer)
3. from base of toes to mid gaiter (short layer)
The control group will be treated with standard short
stretch compression therapy which consists of:
1. a padding layer
2. inelastic short stretch compression bandage
3. a tubular stocking
All layers of standard compression therapy will be
applied from base of toes to just under the knee.
Objectives
Hypotheses
Null Hypothesis T h e r ei sn od i f f e r e n c ei nw o u n ds i z e
reduction with graduated three layer straight tubular
bandaging system when compared to standard short
stretch compression therapy bandage.
Alternative Hypothesis There is a difference in wound
size reduction with graduated three layer straight tubu-
lar bandaging system when compared to standard short
stretch compression therapy bandage.
Primary Outcome
The percentage reduction of wound area from baseline
compared to week 12 following randomisation. The size
of the wound area will be measured by Visitrak wound
measurement system and wound digital photographs.
Secondary Outcomes
1. The proportion of ulcers healed within the trial per-
iod. (Complete healing is defined as full 100% epithelia-
lisation or skin closure without drainage)
2. The incidence of treatment related adverse events
3. Reliability and acceptability (withdrawals)
4. Number of adverse effects and serious adverse
events
5. Quality of Life measures at baseline, at end of treat-
m e n ta n da t3m o n t hf o l l o wu p( S F3 6a n dC a r d i f f
Wound Impact Schedule (CWIS))
6. Self-reported compliance of compression bandage
7. Recurrence rates.
Participant Selection
Type, Source and Number of Participants
Forty six participants will be recruited into the study
from speciality wound clinics. Attendance at the clinics
is by referral for clinical advice and management from
General Practitioners or community nurses.
Study participants will be aged over 18 years of age,
and will have a venous ulcer that is confirmed by CEAP
clinical assessment to be the result of chronic venous
insufficiency. Venous disease can be classified according
to severity, cause and specific abnormality using the
CEAP classification. Use of such a classification
improves the accuracy of the diagnosis. The elements of
CEAP classification are: Clinical severity, Etiology or
cause, Anatomy and Pathophysiology.
Participants may have multiple ulcers but only ONE
will be considered to be the target ulcer. This will be
the largest ulcer (between 1 cm
2 and 20 cm
2) and sepa-
rated from other ulcers by at least 2 cm.
Potential study participants will be provided with a
study information sheet and asked to sign an Informed
Consent Form. Following this, a formal assessment will
be undertaken by a research nurse to determine eligibil-
ity according to the following inclusion and exclusion
criteria.
Inclusion Criteria Male and female study participants
who meet all of the following criteria can be entered
into the study:
1. Presence of a venous ulcer that is confirmed by
CEAP clinical assessment to be the result of chronic
venous insufficiency
2. Aged over 18 years
3. Present with clinical evidence of chronic venous
insufficiency and chronic venous ulceration as evi-
denced by one or more of the following:




4. Chronic venous leg ulcer (target ulcer) that
i. Has been present for at least 4 weeks
ii. is of an area equal to or greater than 1 cm
2
but less than or equal to 20 cm
2 as measured by
digital planimetry techniques
5. Ankle Brachial Pressure index of equal or greater
than 0.8 mmHg
6. Ankle circumference of greater than 20 cm and
less than 30 cm
7. Mobile, and able to return for required treatments
and study evaluations without undue hardship
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9. Able to understand and comply with the require-
ments of the trial
Exclusion Criteria Study participants who meet any of
the following criteria will not be eligible for participation
in this study:
1. Unable or unwilling to wear compression bandage
as directed
2. Evidence of severe liver disease, cardiac disease or
chronic pulmonary disease
3. Medical condition likely to require systemic corti-
costeroids during the study period
4. Any significant condition that may preclude the
participant from the study (e.g. severe depression or
psychiatric illness)
5. Clinically suspected deep vein thrombosis
6. Unable or unwilling to attend clinic for routine
treatment
7. Participation in this trial previously and/or who
dropped out or were withdrawn
Participant Consent
Informed consent will be taken according to ICH GCP
(International Conference on Harmonization Good Clin-
ical Practice). Before recruitment and enrolment into the
study, each prospective participant will be given a full
explanation of the nature and purposes of the study,
and a copy of the Information Sheet to review. Once
the essential study information has been provided, and
the Investigator is assured that each study participant
understands the implications of participating in the
study, the participants will be asked to give consent to
participate in the study by signing and dating the
informed consent form A notation that written
informed consent has been obtained, with date, will be
made in the study participants source documentation
and Case Report Form (CRF). The completed consent
forms will be retained by the Investigator and a copy of
the consent form will be provided to the study
participant.
Criteria for Participant Withdrawal
Participants will be advised that they may withdraw
from the study at any time, for any reason, or if neces-
sary, the Investigator may withdraw a study participant
to protect their health. Study participants may also be
withdrawn for not complying with study procedures
such as not wearing compression bandages. The reasons
for withdrawal will be fully documented in the study
participants notes and CRF. Participants who are with-
drawn or drop out of the randomised treatment will be
allocated for continuing follow up care to the specialty
wound clinic for wound management. All adverse events
will be documented and the reasons for withdrawal
ascertained wherever possible.
Participant Compliance
During the treatment period participant’s compliance
will be assessed. Participants will be asked directly
whether they have been wearing their bandage. Any epi-
sodes of non-compliance will be documented and the
circumstances and duration recorded in the CRF.
Should there be questions or consideration of deviation
from the Protocol, clarification will be sought from the
Study Coordinator. Any study participant treated in a
manner that deviates from the Protocol, or who is
admitted into the study but is not qualified according to
the Protocol, may be ineligible for analysis.
Randomisation
Randomisation will follow a computer generated alloca-
tion schedule (NQuery version 7), using allocation con-
cealment to prevent prior knowledge of treatment
assignment. Numbers will be assigned in strict chrono-
logical sequence and study participants will be entered
in sequence. Randomisation in small block sizes (2 and
4) will be stratified by wound clinic site and wound size
≤ 10 cm
2 or >10 cm
2 (assessed from the wound tracings
and digital photography). Each study participant will be
allocated a unique randomisation number on successful
completion of screening.
Patients will be randomised to receive either control
or intervention group using a central computer gener-
ated random number generated by using a central com-
puter generated randomisation sequence. The
randomization code will be sent to the Investigator (or
designee) who will prepare treatments according to the
randomisation code.
To decrease bias and confounders the decision to
accept or reject a participant will be made using inclu-
sion and exclusion criteria. Informed consent will be
obtained from participants prior to obtaining the rando-
misation code. Independent clinicians will assess the
eligibility of the patient, input identifiers on the rando-
misation website interface to document eligibility and
obtain the randomisation number and allocation of ban-
dage type. The compression bandage systems will be
applied according to the computer generated list alloca-
tion. The codes will only be revealed to the researchers
once the recruitment, data collection and wound mea-
surement analysis are completed. The allocation list will
be stored within the Clinical Informatics and Data Man-
agement Centre of the DEPM.
Plan and Trial Design
This pilot study is a randomised, multi-centre clinical
trial to evaluate the efficacy and safety of graduated
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compared with standard compression therapy (control
arm) in participants with chronic venous ulceration.
Neither participants nor study staff will be blinded to
treatment. Screening evaluations will ensure that poten-
tial participants fulfil all requirements for entry into the
study. Forty six study participants will be randomised
(1:1) to either intervention arm or to the control arm of
the study. Study participants will be reviewed weekly
during the 12 week treatment period, and if healed in
treatment period, participant will be also be reviewed
monthly for three months during a subsequent follow
up period.
In the following sections, a detailed description of all
study procedures is given. All study visits and proce-
dures are described and the evaluations performed at
each visit are detailed. An overview and schedule of the
visits and procedures is provided in Table 1.
Screening Evaluation
The screening period will last for one week during
which time study participants will be required to wear
compression bandages as randomised. Prospective parti-
cipants will be informed about all aspects of the clinical
study, including procedures, risks and benefits. Receipt
of this information will be acknowledged for each study
participant through the provision of written informed
consent by the participant. A copy of the information
sheet and consent form will be provided to each
participant.
The following screening assessments will be con-
ducted for each potential participant:
Informed consent; assessment of compliance with the
inclusion and exclusion criteria; patient medical history;
concomitant medications and treatments; physical
examination and target ulcer assessment.
Treatment Period - Day 1
Participants will be bandaged according to their random
number allocation. The intact standard compression
bandage should be removed and the target ulcer and
limb thoroughly cleansed with tap water and soap-free
wash. The wound may be debrided if deemed clinically
necessary as sloughy and exudative wounds with
unhealthy wound beds will take longer to heal. Wound
debridement and exudate management is important in
early stages to ensure adequate wound bed preparation.
The following assessments will be conducted for each
participant: Target Ulcer Assessment, Temperature,
pulse and blood pressure, intercurrent illness and

















Physical Examination X X X X X
Vital Signs X X XXXXXXXXXXXXX X X
Intercurrent Illness X X XXXXXXXXXXXXX X X
Intercurrent Medication X X XXXXXXXXXXXXX X X
Tolerability Assessment X XXXXXXXXXXXXX X X
Target ulcer assessment X X XXXXXXXXXXXXX X X
SF 36 and CWIS X X X
Adverse events X XXXXXXXXXXXXX X X
Compression hosiery fitting/ application X X
2
Check for Ulcer Recurrence XXX













3: If not healed.
X
4: If ulcer has recurred.
*: If target ulcer has completely healed, (defined as 100% epithelialisation with no presence of exudate or scab).
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Events and confirmation of next visit (7 days time).
Treatment Period - Weeks 1 to 12
Participants will return to the study centre weekly fol-
lowing Day 1 for the following assessments: Check
whether the wound has healed, Target Ulcer Assess-
ment, Assessment of tolerability of product (very
comfortable, comfortable, uncomfortable, very uncom-
fortable), Temperature, pulse and blood pressure, inter-
current illness and medication, Adverse Events, SF 36
and CWIS Quality of Life (Week 12 only)
Treatment Period - Early Completion
Once a wound has been judged to be completely healed
(defined as 100% epithelialisation with no presence of exu-
date or scab), participants will be referred for correct fitting
of long-term compression hosiery to prevent recurrence of
venous ulceration. Participants will also receive an educa-
tion pamphlet as a resource on how best to prevent recur-
rence. Participants will proceed to the Follow-Up Period
and will be followed up monthly for 3 months.
Follow-Up Period - Month 1, 2 and 3
Participants whose target ulcer have been judged to be
completely healed by/at 12 weeks of treatment will need
to attend the outpatient department at the treating hos-
pital to be assessed monthly (± 2 days) for 3 consecutive
months during the Follow-Up Period to monitor safety
and recurrence rates. If this is not possible the partici-
pants will be phoned at these intervals and asked about
recurrence.
At each follow up visit the participant will have the
following assessments performed:
◦ Check whether the wound remains healed.
◦ If the target ulcer has recurred ascertain:
- Date of recurrence
- Target Ulcer Assessment
- Determine if study participant has continued
with compression hosiery treatment. If yes, assess
tolerability of compression hosiery (very comfor-
table, comfortable, uncomfortable, and very
uncomfortable). If no; reason why.
◦ Adverse Events. Any untoward medical occurrence
in a trial participant even if it does not necessarily
have a causal relationship with the treatment.
◦ Ulcer treatment - Participants will be referred to
wound clinic care if the ulcer has not healed or has
recurred in the follow up period.
◦ SF 36 and CWIS Quality of Life (Month 3 only).
Study participants whose ulcers have not healed by/at
the 12 week visit will be released from the study into
the care of a wound clinic. All care will be made to
ensure that all adverse events are followed until resolu-
tion. Study schedule outlined in Table 1.
Duration of Treatment Including Follow-Up
The ulcer will be dressed weekly with standard compres-
sion bandage for one week run in period. The treatment
period is 12 weeks duration. All participants will be seen
on a weekly basis by an experienced leg ulcer practitioner.
Additional visits may be necessary if clinically indicated.
Study participants randomised to the intervention group
will be treated with graduated three layer straight tubular
bandage system once per week for 12 weeks. Study partici-
pants randomised to the control group will be treated with
standard compression bandage for 12 weeks.
Study participants whose ulcers heal before or at 12
weeks of treatment will be assessed monthly for 3 con-
secutive months during the Follow-Up Period to moni-
tor for safety and target ulcer recurrence rates. Study
participants whose ulcers have not healed at the 12
week visit will be released from the study and returned
to the care of the speciality wound clinic. All care will




A physical assessment of the participant will include
demographics (gender, date of birth, height, weight,
smoking and alcohol history), vascular assessment taking
particular note of any signs and symptoms of chronic
venous insufficiency, ankle mobility, vital signs (tem-
perature, pulse and supine blood pressure) and Ankle-
Brachial Index to assess the arterial supply of the target
limb. This is a non-invasive procedure that involves
measuring blood pressure on the foot and on the arm
and is necessary prior to application of any compression
bandage to exclude arterial disease. Participants will not
be included in the trial if they have an Ankle Brachial
index of less than 0.8.
Target Ulcer Assessment
The target ulcer should be identified from the entrance
criteria (i.e. largest ulcer on limb and separated from
other ulcers by at least 2 cm).
Visitrak wound tracing The ulcer outline will be traced
and the ulcer area calculated to determine ulcer size
Digital photo of ulcer The ulcer will be photographed
using a digital camera and image saved and sent to an
independent assessor who will be blinded to treatment
assignment. The target ulcer will also be photographed
when complete epithelialisation is evident.
Percentage of Granulation Tissue The ulcer will be
assessed for quality of wound bed tissue (red <25%, red
25%-50%, red 50%-75%, >75%, hypergranulated, other).
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probe (Grade I, II, III, IV).
Surrounding Skin The condition of the surrounding
skin will be assessed (normal, dry, wet eczema, dry
eczema, erythema, other).
Exudate level T h el e v e lo fe x u d a t ew i l lb ea s s e s s e d
(copious, medium, minimal, nil).
SF36 and CWIS Quality of Life
Participants will be asked to complete the SF36 and
CWIS Quality of Life surveys at screening visit and at
completion of study treatment. A copy will be retained
in the CRF.
Statistical Methodology
Statistical summaries and analyses of data will be per-
formed at Monash University.
Sample Size and Analysis plan
Participants will be randomised to graduated three layer
straight tubular bandaging system (3L) or to a standard
short stretch compression bandaging system. From a
previous study [25] we anticipate an average reduction
of 20% in wound size from baseline to follow-up in the
group that receives 3L. To detect with 80% power a dif-
ference in the mean percentage reduction of 50% in the
g r o u pw i t hs t a n d a r dc o m p r e s s i o nv e r s u s2 0 %i nt h e3 L
group requires 18 participants per group. This assumes
a two-sided z-test (alpha = 0.05) of mean log (Area2/
Area1) where Area2 is the area of the wound at follow-
up and Area1 is the area of the wound at baseline. Per-
centage reduction is defined as 100(Area2-Area1)/Area1
and percentage reductions of 20% and 50% correspond
to a difference in means of 0.47 on the scale of analysis
(log(Area2/Area1)). From a previous study (Vowden et
al, 2007) we estimate the standard deviation of log
(Area2/Area1) to be 0.5 in each group. If a wound has
completely healed and Area2 = 0 then we will use log
(min (Area2)/Area1) in analysis where Area2 = Area1/
100 is the smallest observed wound area at follow-up
among those participants whose wounds did not com-
pletely heal. A two-sided p-value of 0.05 will be consid-
ered to be statistically significant.
With 18 participants per group the study will have
55% power to address the secondary endpoint of com-
plete healing if the effect of standard compression is to
improve the rate of healing from 20% of participants
fully healed (with 3L) to 60% with standard
compression.
T h ea n a l y s i so ft h ep r i m a r ye n d p o i n tw i l lb eb yz - t e s t
and linear regression if the distribution of log (A2/A1)
is reasonably symmetric. It is unclear from previous stu-
dies whether this will be the case. If necessary the analy-
sis of hypothesis 1 will be by non-parametric Wilcoxon
rank-sum test. If major differences are evident in key
v a r i a b l e s( a g e ,g e n d e r ,e t h n i c i t y ,B M I ,s m o k i n g ,A B P I ,
ankle and calf circumference, range of ankle mobility,
past medical history- diabetes, anaemia, hypertension,
past surgical history-hip surgery, venous surgery/liga-
tion, DVT, medication history) between allocated groups
at baseline, then the baseline values will be included as
covariates in a second linear regression model for the
primary outcome. Imbalance will be defined as a differ-
ence in means (on a log scale for variables following a
skewed distribution) of ≥ 0.33 standard deviations or,
for binary and categorical variables a relative risk of ≥ 2
(where prevalence is ≥ 10%).
Finally, 18 participants per group need to have wound
area assessed at the end of the 12-week follow-up. To
allow for loss-to-follow-up of 20% of participants
between baseline and follow-up we will randomise 23
participants to each arm.
Pilot study sample size justification
We will recruit 46 participants in total to enable the
estimation of the between-person variability in percen-
tage reduction in wound size from baseline to 12 weeks.
There are insufficient previous studies to ascertain a
likely value for this variability for use in power calcula-
tions for a fully powered trial.
The analysis principle for the primary outcome will be
Intention-to-treat. The data will be analysed according
to the treatment group to which participants are rando-
mised even if they do not comply fully with their treat-
ment. If participants drop out of the study they will be
asked if they would still be prepared to return at the 12
week end of treatment schedule for target ulcer
measurement.
Data Management
Data management will be managed by Monash Univer-
sity. A Data Management Plan will be completed outlin-
ing the data management process prior to the collection
and analysis of study data. Original on-screen Case
Report Forms will be used when entering information
into the computer database. Entered data will later be
double-checked against original case report forms for
accuracy. All case report forms and data checking
records will be retained as permanent records of the
study.
Trial Approval and Conduct
Regulatory Approval
The Principal Investigator will ensure that this study is
conducted in full compliance with the Protocol, the
Declaration of Helsinki, the International Conference
on Harmonization (ICH) guideline for GCP, Austra-
lian Therapeutic Goods Administration (TGA) regula-
tions, and all other applicable local laws and
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rights, safety, and well being of study participants are
protected.
Ethical Considerations
The monitoring and safety guidelines are outlined in
the Monitoring Guidelines for the study. This study
will be carried out according to the Declaration of Hel-
sinki, the Notes for Guidance on Good Clinical Prac-
tice (2000) (CPMP/ICH/135/95) and the ICH GCP
Guidelines. The Protocol has approval from Alfred
Health, Austin Health, Melbourne Health, Queensland
Health and Monash University Human Research Ethics
Committees (HREC)/Institutional Review Board (IRB).
The Investigator will report study progress to the
HREC/IRB as required or at intervals not greater than
one year.
Trial Monitoring
T h et a s ko ft h eS t u d yM o n i t o ri st og u a r a n t e et h eb e s t
conduct of the study through frequent contacts by
phone and in person with the responsible Investigator
and research nurse, in accordance with the Monitor’s
Operating Procedures, with the purpose of facilitating
the work and fulfilling the objectives of the study. These
site visits will enable the Monitor to maintain current,
personal knowledge of the study through review of the
records, comparison with source documents, and obser-
vation and discussion of the conduct of the study with
the Investigator. Site monitoring will occur at 4-6 week
intervals. Case Report Forms (CRF) will be reviewed and
compared with source documents. Queries will be iden-
tified and a request for further information will be
sought. The organisation, monitoring, supply of study
materials and quality assurance of the present clinical
study is the responsibility of Carolina Weller (Monash
University PhD student). In order to ensure the accuracy
of data, direct access to source documents by the repre-
sentatives of both the Study Monitor and regulatory
authorities is mandatory. Anonymity of the study parti-
cipants will be maintained at all times.
Discussion
The 3VSS2008 trial is a multicentre open label parallel
group randomised trial to determine whether graduated
three layer straight tubular bandaging system is more
effective in mean percentage reduction of healing
venous ulcers when compared to a standard short
stretch compression bandaging system in the manage-
ment of people with venous ulceration. This is a pilot
trial to determine the recruitment rate and assess the
variability in the percentage reduction of wound size in
each bandaging group for use in sample size calculation
for a fully powered trial. The results will inform the
design of a larger trial that could provide more precise
estimates of the efficacy of the intervention.
Current study status
The study commenced recruitment in February 2009
and has recruited 25 participants. Patient follow up has
commenced with 12 participants who have healed. Due
to slow recruitment numbers two other sites have been
approached to recruit for the study. Expected recruit-
ment completion is July 2010.
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